Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Enoxaparin on anti-factor Xa levels in myocardial infarction patients with acute coronary syndrome
IRCT20120215009014N198Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Sep 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of enoxaparin in myocardial infarction (MI) and acute coronary syndrome (ACS), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Serum activated anti-factor Xa level. Started Sep 2016; status: completed.
02
Drugs
enoxaparin
03
Conditions
myocardial infarction (MI)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20120215009014N198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N198.